Last update Jan. 19, 2022
Isoprenaline is a sympathomimetic beta-adrenergic agonist. It increases heart rate, causes peripheral vasodilation and has bronchodilator properties. Indicated in the treatment of bradycardia and heart block, and bronchoconstriction in anesthesia. Intravenous or inhaled administration
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, moderate protein binding) makes transfer to breast milk possible, but its very short half-life (5 minutes) makes it difficult.
Its very low oral bioavailability minimizes the passage into plasma of the infant from ingested breast milk, except in the premature and in the immediate neonatal period in which there may be greater intestinal permeability.
Depending on the clinical status of the mother, half an hour (6 T½) after finishing the administration of isoprenaline, she can breastfeed without risk to the infant.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.